The urticaria drug market is dominated by oral medications, including steroids and second-generation, nondrowsy antihistamines, prescribed for both chronic inducible and chronic spontaneous…
The chronic obstructive pulmonary disease (COPD) therapy market is continuing its gradual shift away from long-acting beta2 agonist/inhaled corticosteroid fixed-dose combinations (LABA/ICSFDCs)…
Targeted therapies and various biomarkers (e.g., RAS, BRAF, MSI-H,dMMR) play an important role in the treatment of colorectal cancer. Treatment is becoming increasingly segmented by the side on…
The wet age-related macular degeneration (AMD) therapy market has long been dominated by three VEGF inhibitors—Roche / Genentech / Chugai’s Avastin, Roche / Genentech / Novartis’s Lucentis,…
The Parkinson’s disease (PD) therapy market is changing: the first new levodopa formulation (Rytary) in over a decade launched in 2015 and more are on the horizon (e.g., ABBV-951, IPX203); two…
The launch of several novel therapies and multiple label expansions of premium-priced agents will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over the ten-year…
Clarivate Epidemiology’s coverage of polycystic kidney disease comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France…
DRG Epidemiology’s coverage of tuberous sclerosis comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany,…
Clarivate Epidemiology’s coverage of amyotrophic lateral sclerosis (ALS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United…
The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will continue to fragment as new entrants drive further shifts in a complicated treatment…
Prostate cancer is the most common cancer among men in developed countries. Hormonal agents are the mainstay of treatment for prostate cancer and are routinely used across lines. Zytiga (Johnson &…
The rising rates of antimicrobial resistance have created an urgent need for antibiotics with activity against drug-resistant gram-negative pathogens (GNPs). Antibiotics such as carbapenems, which…
Clarivate’s Epidemiology's coverage of GIST comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of GIST for each country, as…
DRG Epidemiology's coverage of progressive supranuclear palsy (PSP) comprises epidemiological estimates of diagnosed prevalence across the major mature pharmaceutical markets (the United…
DRG Epidemiology's coverage of social anxiety disorder (SAD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…